Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03902600 · ClinicalTrials.gov registry record

A Study of Photon and Proton Chemoradiotherapy as Definitive or Neoadjuvant Therapy in Non-Metastatic Pancreatic Cancer

A clinical trial of Pancreatic Cancer, sponsored by Mayo Clinic.

Active
Registry status
103
Enrollment target
2
Study locations

NCT03902600: Active study of Pancreatic Cancer, sponsored by Mayo Clinic.

NCT03902600 is a study of Pancreatic Cancer that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 103 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (74% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03902600, a study of Pancreatic Cancer, is active but no longer recruiting, sponsored by Mayo Clinic.

ACTIVE NOT RECRUITING
Registry status
103 participants
Enrollment target
2
Study locations

Study Summary

This study will observe side effects for patients who receive a 3-week course of radiation and chemotherapy for pancreas cancer. Blood samples will be collected before and after treatment to assess pancreas cancer DNA levels and its impact on outcomes.

Primary Outcome

Acute grade 3 or higher gastrointestinal (GI) adverse events (AEs) possibly, probably, or definitely related to hypofractionated concurrent chemoradiotherapy (CRT)

Conditions Studied

Interventions

  • RADIATION Moderately Hypofractionated RT

Study Locations (2)

Arizona

  • Mayo Clinic in Arizona - Scottsdale

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2018-05-10
Est. Completion 2026-08-31
Mayo Clinic

2,844 total trials

What the registry record for NCT03902600 still lists

NCT03902600 is an observational study that tracks outcomes without assigning an intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (74% lower).

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Moderately Hypofractionated RT is the first listed.

NCT03902600 reports a single indexed study location in Arizona, Minnesota.

Frequently Asked Questions

What is clinical trial NCT03902600 about?

NCT03902600 is a clinical study titled "A Study of Photon and Proton Chemoradiotherapy as Definitive or Neoadjuvant Therapy in Non-Metastatic Pancreatic Cancer". This study will observe side effects for patients who receive a 3-week course of radiation and chemotherapy for pancreas cancer. Blood samples will be collected before and after treatment to assess pancreas cancer DNA levels and its impact on outcomes.

What is the current status of trial NCT03902600?

This trial is currently active not recruiting. The enrollment target is 103 participants. The study started on 2018-05-10. Estimated completion is 2026-08-31.

What conditions does trial NCT03902600 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT03902600?

The interventions under investigation include: Moderately Hypofractionated RT (RADIATION).

Who is sponsoring clinical trial NCT03902600?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03902600 being conducted?

This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03902600's enrollment target sits among peer trials

103 104th of 278 higher than 175 of 278 other Pancreatic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04690348 · 103 participants · Phase 2

    Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

  • NCT05282277 · 103 participants · Phase 4

    Examining the Effects of Estradiol on Neural and Molecular Response to Reward

  • NCT05566769 · 103 participants · NA

    Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

  • NCT05834478 · 103 participants · Phase 3

    Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03902600, the US trial registry maintained by the National Library of Medicine. NCT03902600 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.